Skip to content
2000
Volume 21, Issue 24
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Hydrogen sulfide (HS), as one of the endogenous gasotransmitters, has shown great potential in treating cardiovascular diseases (CVDs). HS plays a protective role in CVDs by removing reactive oxygen species (ROS), promoting vasodilation, inhibiting myocardial hypertrophy, preventing thrombosis, and protecting mitochondria. However, there still exist some problems for HS as drugs such as challenging delivery, uncontrollable release rate, and other drug developability issues. Addressing these problems, the prodrug strategy shows great potential. Therefore, a key issue on the HS-based therapeutics is developing appropriate H2S prodrugs. In this review, we mainly discussed the mechanism of HS against CVDs and reviewed the cardiovascular effects of current HS prodrugs.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026621666210831163817
2021-09-01
2025-12-07
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026621666210831163817
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test